BRYXTA 100MG INJ

Product Description

• Active Ingredient: Bevacizumab 100 mg per 4 mL vial.
• Mechanism of Action: Bevacizumab works by binding to a protein called Vascular Endothelial Growth Factor (VEGF). VEGF normally promotes the growth of new blood vessels that supply oxygen and nutrients to tumors. By inhibiting VEGF, the medication cuts off the tumor's blood supply, causing it to shrink or stop growing and spreading.
• Uses: Bryxta 100mg is used to manage several types of advanced or metastatic cancers, including:
  • Colorectal cancer
  • Non-small cell lung cancer
  • Kidney cancer (renal cell carcinoma)
  • Cervical cancer
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • Recurrent glioblastoma (brain tumor)
  • Hepatocellular carcinoma (liver cancer)
• Storage: The injection should be stored in a refrigerator at 2C to 8C (36F to 46F) and protected from light. It must not be frozen